化疗再挑战/再引入在转移性结直肠癌三线治疗中的应用现状及展望

打开文本图片集

关键词：化疗再挑战/再引入；转移性结直肠癌；三线治疗；抗肿瘤药物；治疗结果 中图分类号：R735.3文献标志码：A文章编号：2097-7174（2026）03-0283-08 DOI：10.3969/j. issn. 2097-7174. 2026.03.014

Application and prospects of chemotherapy rechallenge/reintroduction inthird-linetreatmentformetastaticcolorectal cancer

CHEJie，HUANGLi （1.TheFirst Clinical MedicalSchoolofGannan Medical University；2.TheFirstAffiiatedHospitalofGannan Medical University，Ganzhou，Jiangxi ）

Abstract：Patients with metastaticcolorectal cancer（mCRC）have limitedoptions forthird-linetherapyafterfailureof first-andsecod-lintreatments.hemediaprogresion-frsrvivalforregoraenib，trifludine/tipiacil，ndfrntinib is less than 4 months，with objective response rates below 5% ，indicating limited clinical benefit.Chemotherapy re-chalenge/re-introductionoffersapotentialthird-linetreatmentoptionbyreactivatingprioroxaliplatin-oririnotecanbasedregimens.Thisarticlesystematicallyreviewstherelevantliteratureandanalyzesthecurrentstatusofclinicalstudieson chemotherapyrechallenge/reintroductionandthefactors affecting effcacyand safety.Anumberof studies have shown that chemotherapyrechalenge/reintroductionhasacertaineffct inthe third-linetreatmentofmCRC，especiallforpatients with goodresponse to previous chemotherapy.Whenthe treatment interval is greater than6 months，patients mayachieve bettertherapeuticeffects.Thesafetyofchemotherapyrechallenge/reintroductionneedstobecloselymonitoredandmanaged toachieve thebest balance between eficacyandadverse reactions.Chemotherapyre-challnge/re-introduction provides a newoptionforthird-line treatmentof mCRC.In clinical appication，itis necessary tocomprehensivelyconsiderthe individual characteristicsof patients，previous treatment reactionsand potential adversereactions，and formulate individualizedtreatment plans.In the future，more prospectiveand large sample studiesare neded to further verifyits efficacy and safety.

Keywords：Chemotherapyrechalenge/reintroduction；Metastaticcolorectalcancer；Third-line treatment；Antineoplastic agents；Treatment outcome

结直肠癌（Colorectalcancer，CRC）是常见的消化系统恶性肿瘤之一，是50岁以下成年男性癌症死亡的主要原因，也是女性癌症死亡的第二大原因[1]。（剩余19338字）